HK Stock Movement | JACOBIO-B (01167) Surges Over 11% Again After Receiving RMB125M Initial Payment from Oceanpine Capital

Stock News12-10

JACOBIO-B (01167) rose over 11% again, gaining 10.28% to HK$8.69 by the time of writing, with a turnover of HK$73.82 million. The company recently announced it had received an initial payment of RMB125 million from Oceanpine Capital under the capital increase and equity transfer agreements. This payment strengthens the group's cash reserves and supports the advancement of its innovative oncology therapy pipeline.

In October, JACOBIO-B disclosed agreements with Oceanpine Capital and an industrial partner for capital injection and equity transfer. Under the deal, Oceanpine Capital will acquire an 80% stake in Jacobio Rui Kang for RMB125 million upfront and an additional RMB75 million in milestone payments. Post-transaction, JACOBIO-B's stake in Jacobio Rui Kang will reduce to 10%. The company stated that this transaction aligns with its strategic focus on key oncology pipeline products targeting critical cellular pathways.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108634669?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 14:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108634669","market":"sg","top_or_hot":-1,"title":"HK Stock Movement | JACOBIO-B (01167) Surges Over 11% Again After Receiving RMB125M Initial Payment from Oceanpine Capital","media":"Stock News","content":"<p>JACOBIO-B (01167) rose over 11% again, gaining 10.28% to HK$8.69 by the time of writing, with a turnover of HK$73.82 million. The company recently announced it had received an initial payment of RMB125 million from Oceanpine Capital under the capital increase and equity transfer agreements. This payment strengthens the group's cash reserves and supports the advancement of its innovative oncology therapy pipeline.</p>\n<p>In October, JACOBIO-B disclosed agreements with Oceanpine Capital and an industrial partner for capital injection and equity transfer. Under the deal, Oceanpine Capital will acquire an 80% stake in Jacobio Rui Kang for RMB125 million upfront and an additional RMB75 million in milestone payments. Post-transaction, JACOBIO-B's stake in Jacobio Rui Kang will reduce to 10%. The company stated that this transaction aligns with its strategic focus on key oncology pipeline products targeting critical cellular pathways.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | JACOBIO-B (01167) Surges Over 11% Again After Receiving RMB125M Initial Payment from Oceanpine Capital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | JACOBIO-B (01167) Surges Over 11% Again After Receiving RMB125M Initial Payment from Oceanpine Capital\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-10 14:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JACOBIO-B (01167) rose over 11% again, gaining 10.28% to HK$8.69 by the time of writing, with a turnover of HK$73.82 million. The company recently announced it had received an initial payment of RMB125 million from Oceanpine Capital under the capital increase and equity transfer agreements. This payment strengthens the group's cash reserves and supports the advancement of its innovative oncology therapy pipeline.</p>\n<p>In October, JACOBIO-B disclosed agreements with Oceanpine Capital and an industrial partner for capital injection and equity transfer. Under the deal, Oceanpine Capital will acquire an 80% stake in Jacobio Rui Kang for RMB125 million upfront and an additional RMB75 million in milestone payments. Post-transaction, JACOBIO-B's stake in Jacobio Rui Kang will reduce to 10%. The company stated that this transaction aligns with its strategic focus on key oncology pipeline products targeting critical cellular pathways.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01167","symbol_name":"加科思-B","start_time":0,"source_url":"","article_id":"1108634669","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108634669","pubTimestamp":1765346665,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JACOBIO-B (01167) rose over 11% again, gaining 10.28% to HK$8.69 by the time of writing, with a turnover of HK$73.82 million. The company recently announced it had received an initial payment of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01167":"加科思-B","BK1574":"生物医药B类股","BK1161":"生物科技"},"translate_title":"港股动向|雅可比-B(01167)获Oceanpine Capital首付人民币1.25亿元再升逾11%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":1},"content_text":"JACOBIO-B (01167) rose over 11% again, gaining 10.28% to HK$8.69 by the time of writing, with a turnover of HK$73.82 million. The company recently announced it had received an initial payment of RMB125 million from Oceanpine Capital under the capital increase and equity transfer agreements. This payment strengthens the group's cash reserves and supports the advancement of its innovative oncology therapy pipeline.\nIn October, JACOBIO-B disclosed agreements with Oceanpine Capital and an industrial partner for capital injection and equity transfer. Under the deal, Oceanpine Capital will acquire an 80% stake in Jacobio Rui Kang for RMB125 million upfront and an additional RMB75 million in milestone payments. Post-transaction, JACOBIO-B's stake in Jacobio Rui Kang will reduce to 10%. The company stated that this transaction aligns with its strategic focus on key oncology pipeline products targeting critical cellular pathways.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108634669","isCrawlerRequest":true}